Met Life Investment Management, LLC Vaxart, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

38 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jun 14, 2023
BUY
$0.75 - $2.24 $50,165 - $149,826
66,887 New
66,887 $64,000
Q3 2022

May 10, 2024
BUY
$2.09 - $4.5 $50,120 - $107,914
23,981 Added 55.89%
66,887 $145,000
Q3 2022

Jun 14, 2023
BUY
$2.09 - $4.5 $139,793 - $300,991
66,887 New
66,887 $145,000
Q3 2022

Mar 22, 2023
BUY
$2.09 - $4.5 $50,120 - $107,914
23,981 Added 55.89%
66,887 $145,000
Q3 2022

Nov 14, 2022
BUY
$2.09 - $4.5 $50,120 - $107,914
23,981 Added 55.89%
66,887 $146,000
Q2 2022

May 10, 2024
SELL
$2.7 - $5.28 $69,662 - $136,229
-25,801 Reduced 37.55%
42,906 $150,000
Q2 2022

Jun 20, 2023
BUY
$2.7 - $5.28 $115,846 - $226,543
42,906 New
42,906 $150,000
Q2 2022

Mar 22, 2023
SELL
$2.7 - $5.28 $69,662 - $136,229
-25,801 Reduced 37.55%
42,906 $150,000
Q2 2022

Aug 11, 2022
SELL
$2.7 - $5.28 $69,662 - $136,229
-25,801 Reduced 37.55%
42,906 $150,000
Q1 2022

May 10, 2024
BUY
$4.29 - $6.64 $294,753 - $456,214
68,707 New
68,707 $346,000
Q1 2022

Jun 20, 2023
BUY
$4.29 - $6.64 $294,753 - $456,214
68,707 New
68,707 $346,000
Q1 2022

Mar 22, 2023
BUY
$4.29 - $6.64 $105,920 - $163,941
24,690 Added 56.09%
68,707 $346,000
Q1 2022

May 12, 2022
BUY
$4.29 - $6.64 $105,920 - $163,941
24,690 Added 56.09%
68,707 $346,000
Q4 2021

May 17, 2024
BUY
$5.77 - $7.96 $53,476 - $73,773
9,268 Added 26.67%
44,017 $275,000
Q4 2021

Jun 21, 2023
BUY
$5.77 - $7.96 $253,978 - $350,375
44,017 New
44,017 $275,000
Q4 2021

Mar 22, 2023
BUY
$5.77 - $7.96 $53,476 - $73,773
9,268 Added 26.67%
44,017 $275,000
Q4 2021

Feb 15, 2022
BUY
$5.77 - $7.96 $53,476 - $73,773
9,268 Added 26.67%
44,017 $276,000
Q3 2021

May 17, 2024
SELL
$6.67 - $9.8 $66,633 - $97,902
-9,990 Reduced 22.33%
34,749 $276,000
Q3 2021

Jun 21, 2023
BUY
$6.67 - $9.8 $231,775 - $340,540
34,749 New
34,749 $276,000
Q3 2021

Mar 22, 2023
SELL
$6.67 - $9.8 $66,633 - $97,902
-9,990 Reduced 22.33%
34,749 $276,000
Q3 2021

Nov 15, 2021
SELL
$6.67 - $9.8 $66,633 - $97,902
-9,990 Reduced 22.33%
34,749 $276,000
Q2 2021

May 17, 2024
BUY
$5.06 - $10.78 $198,260 - $422,381
39,182 Added 705.09%
44,739 $335,000
Q2 2021

Jun 21, 2023
BUY
$5.06 - $10.78 $226,379 - $482,286
44,739 New
44,739 $335,000
Q2 2021

Mar 22, 2023
BUY
$5.06 - $10.78 $198,260 - $422,381
39,182 Added 705.09%
44,739 $335,000
Q2 2021

Aug 16, 2021
BUY
$5.06 - $10.78 $198,260 - $422,381
39,182 Added 705.09%
44,739 $335,000
Q1 2021

May 17, 2024
BUY
$5.64 - $23.33 $31,341 - $129,644
5,557 New
5,557 $33,000
Q1 2021

Jun 26, 2023
BUY
$5.64 - $23.33 $31,341 - $129,644
5,557 New
5,557 $33.6 Million
Q1 2021

Mar 22, 2023
SELL
$5.64 - $23.33 $104,007 - $430,228
-18,441 Reduced 76.84%
5,557 $33,000
Q1 2021

May 14, 2021
SELL
$5.64 - $23.33 $104,007 - $430,228
-18,441 Reduced 76.84%
5,557 $34,000
Q4 2020

May 24, 2024
BUY
$3.5 - $7.98 $6,006 - $13,693
1,716 Added 7.7%
23,998 $137,000
Q4 2020

Jun 22, 2023
BUY
$3.5 - $7.98 $83,993 - $191,504
23,998 New
23,998 $137,000
Q4 2020

Mar 22, 2023
BUY
$3.5 - $7.98 $6,006 - $13,693
1,716 Added 7.7%
23,998 $137,000
Q4 2020

Feb 16, 2021
BUY
$3.5 - $7.98 $6,006 - $13,693
1,716 Added 7.7%
23,998 $137,000
Q3 2020

Jun 26, 2023
BUY
$4.78 - $16.97 $106,507 - $378,125
22,282 New
22,282 $148,000
Q2 2020

May 24, 2024
BUY
$1.68 - $8.85 $37,433 - $197,195
22,282 New
22,282 $197 Million
Q2 2020

Jun 26, 2023
BUY
$1.68 - $8.85 $37,433 - $197,195
22,282 New
22,282 $197,000
Q2 2020

Mar 22, 2023
SELL
$1.68 - $8.85 $74,936 - $394,754
-44,605 Reduced 66.69%
22,282 $197,000
Q2 2020

Aug 14, 2020
BUY
$1.68 - $8.85 $37,433 - $197,195
22,282 New
22,282 $197,000

Others Institutions Holding VXRT

# of Institutions
107
Shares Held
37.7M
Call Options Held
188K
Put Options Held
180K
View Full List

About Vaxart, Inc.

VXRT Quotes by TradingView
  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $86M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email